Foley Partners Lawrence Vernaglia and Judith Waltz will be speaking at the AHLA Institute for Medicare and Medicaid Payment Issues.
On Wednesday, March 21st from 4:45 – 5:45 pm, Foley Partner Judith Waltz will co-present “Administrative Enforcement Tools” with Julie Burns.
Their session will cover:
- Medicare: Billing privileges revocations and denials, enrollment moratoria
- Payment suspensions (recent Medicaid targets as well as Medicare “sweeps”)
- OIG CMPs and Exclusions–finalized rules and new developments
- Medicaid enforcement: CMS-led efforts, reciprocal terminations, enrollment actions
Also on Wednesday, March 21st from 4:45 – 5:45 pm, Foley Partner Lawrence Vernaglia will co-present “Provider-Based Status, Under Arrangements, Enrollment, and Related Medicare Requirements” with Andrew Ruskin.
Their session will cover:
- Operational Issues faced by entities relating to BBA Section 603 (site neutrality) implementation
- The recent reimbursement changes for 340B drugs
- Changes to the reimbursement methodology for non-grandfathered sites
- Assessment of “mid-build” exception implementation
For more information and to register, visit the AHLA event website.
People
Related Insights
02 December 2024
Foley Viewpoints
Manufacturer and Distributor’s Relationship Is Not a Franchise Under Connecticut Law
The Superior Court of Connecticut addressed a contractual dispute between a manufacturer of snow removal equipment and its distributor.
02 December 2024
Foley Viewpoints
Louisiana Based Franchisor and Its Employees Cannot Avoid Personal Jurisdiction in Washington State
Washington-state based franchisees Greg and Gabriela Skistimas brought suit against Hotworx Franchising LLC in the U.S. District Court for the Western District of Washington alleging misleading and unfair practices related to franchise disclosure and marketing in connection with the sale of HOTWORX sauna and fitness studio.
02 December 2024
Health Care Law Today
GLP-1 Drugs: Brand Companies Push FDA to Limit Compounding
Brand companies who own GLP-1 products have been pushing the Food and Drug Administration to limit their compounding.